8 research outputs found
Prognostic value of serum M-protein doubling time at escape from plateau of multiple myeloma
No full textIntensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma
No full textResponse rate and survival after conventional chemotherapy for multiple myeloma by hospitals with different inclusion rates of patients to the trials. A Finnish Leukemia Group study
No full textResponse level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study
No full textModified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study
No full textEtoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) as outpatient salvage therapy for refractory multiple myeloma
No full text
